Abstract: A heat-sensitive recording material including: a substrate; a heat-sensitive color developing layer over the substrate, the heat-sensitive color developing layer composed mainly of a leuco dye and a color developer that develops color of the leuco dye upon heating; and a protective layer over the heat-sensitive color developing layer, the protective layer composed mainly of a water-soluble resin and a crosslinking agent, wherein the protective layer contains diacetone-modified polyvinyl alcohol as the water-soluble resin, and N-aminopolyacrylamide as the crosslinking agent.

Abstract: A non-ionic surfactant aggregate comprises a water insoluble biocidally active ingredient, a non-ionic surfactant system, and water. The non-ionic surfactant system comprises first and second non-ionic surfactants.

Abstract: A system for impregnating a superconductive wire surrounded by insulation with a resin provided in liquid form in a vessel, has an input arrangement that introduces the wire into the vessel, a transport device that moves the wire through the resin in the vessel and a pressure applicator that applies pressure to the wire, transversely to its length, at at least one location within the vessel while in contact with the resin, so as to expel gases otherwise trapped within the insulated wire. Each pressure applicator is formed by a co-operative pair of pinch rollers, with one pinch roller of each pair being doubly flanged to provide a substantially central recess to accommodate the insulated wire, and the other pinch roller of each pair is formed with a central tongue dimensioned to enter the recess to trap the wire therein and apply pressure thereto.

Abstract: The invention provides methods for correcting misincorporation of a nucleotide in a primer during a sequencing-by-synthesis reaction by using both a polymerase substantially lacking in exonuclease activity and an enzyme, preferably a polymerase, having exonuclease activity.

Abstract: The invention relates to methods and kits for the amplification, detection and quantification of a nucleic acid from a sample. The methods of the invention may be used in a wide range of applications, including, but not limited to, the detection and quantification of fetal nucleic acid from maternal plasma, the detection and quantification of circulating nucleic acids from neoplasms (malignant or non-malignant), accurate pooling analysis for low frequency alleles, or any other application requiring sensitive quantitative analysis of nucleic acids.

Abstract: The present invention relates to microarrays, in which the probes are each applied multiple times and in different concentrations to a carrier. In particular, the present invention relates to a method for detecting specific molecules in a biological sample, using which the dynamic range of the detection is expanded.

Abstract: There is disclosed a diagnostic or prognostic assay for cancer, particularly gastrointestinal and esophageal adenocarcinoma. Specifically, the present invention provides a methylation pattern that can be assayed by standard methylation assays of CpG islands, including which genes are hypermethylated and which genes are unmethylated in gastrointestinal and esophageal adenocarcinomas, Barrett's esophagus, and normal squamous mucosa.

Abstract: Trp cage binding domains polypeptides are disclosed. The Trp cage binding domains have the generic formulae of SEQ ID NO: 2, 7, 10 or 11. They can be efficiently produced and screened using phage display technology.

Abstract: The invention provides a rapid high throughput screening process to identify genotoxic compounds. This is accomplished by using a set of biomarker predictor genes that selectively screen for genotoxic or non-genotoxic compounds.

Abstract: Embodiments of the invention provides methods, computer software products and systems for arranging polymers during combinatorial polymer synthesis so that the border or edge between synthesis site is minimized. In one embodiment, travelling salesman algorithm is used to minimize the edges. In another embodiment, a locally greedy optimization method is provided. In addition, methods and software products are provided for solving the robust arrangement problem for multi-probe gene expression arrays.

Abstract: The present invention provides a method of asphaltene control in a hydrocarbon fluid, the method employing a composition comprising: a dispersant of formulae (I) or (II), including salts thereof, wherein T or T? is hydrogen or a polymerizing terminating group; A is C16-20 alkylene or alkenylene group; B is C10-20 alkylene or alkenylene group; Z and Z? are the residue of a polyamine or polyimine; n is 2 to 50; m is 0 to 25; p and p? are 2 or more, in one embodiment not greater than 2000 and in another embodiment not greater than 1000; A? is C8-20 alkylene or alkenylene group; n? is 2 to 10; and the weight ratio of T-(O-A-CO)n (O—B—CO)m to Z or T?-(O-A?-CO)n to Z? is at least 5:1.

Abstract: A method for sealing a subterranean zone is disclosed. The method includes the steps of preparing a wellbore fluid, placing the wellbore fluid into at least a portion of an annular space between the sidewalls of a wellbore and the exterior of a casing string disposed in the wellbore, and allowing the wellbore fluid to solidify therein, wherein the wellbore fluid includes an oleaginous fluid as the continuous phase of the wellbore fluid, a non-oleaginous fluid as the discontinuous phase of the wellbore fluid, and about 5 to about 50 pounds per barrel of a thermally activated hydrocarbon gellant.

Abstract: The present invention relates to a method of treating porous and permeable underground formations or cavities of reservoir rock or sand foundation type. The method consists in injecting a liquid composition comprising microgels into the formations in order to reduce the production of water, gas or sands, and/or for zone abandonment.

Abstract: A lubricating oil composition of the present invention which contains an ether ashless friction modifier is applicable to a sliding surface having a low friction sliding member, is capable of imparting excellent low friction characteristics thereto and, in particular, is capable of giving a fuel saving effect when applied to an internal combustion engine.

Abstract: This invention relates to a method of lubricating an internal combustion engine comprising at least one of a crankcase, a gear and a wet-clutch, said method comprising supplying to said crankcase, gear, and wet-clutch a lubricating composition containing: (a) an oil of lubricating viscosity; (b) a boron containing compound; and (c) a friction modifier.

Abstract: The present invention is directed to a soluble oil composition capable of forming stable emulsions exhibiting superior performance and possessing excellent utility as cutting oil for machines. The composition comprises an overbased alkaline earth metal sulfonate possessing anti-wear properties.

Abstract: This invention relates to a method of lubricating an internal combustion engine comprising at least one of a crankcase, a gear and a wet-clutch, said method comprising supplying to said crankcase, gear and wet-clutch a lubricating composition comprising: (a) an oil of lubricating viscosity; and (b) a viscosity modifier with a number average molecular weight from 1000 to 75,000, wherein the lubricating composition has a SAE viscosity grade from XW—Y, wherein X is from 0 to 20 and Y is from 20 to 50; and wherein the lubricating composition has a phosphorus content from a metal hydrocarbyl dithiophosphate of 0.12 wt % or less.

Abstract: Provided are formulations, methods of making, and methods of using one or more isomerized base oils in a turbine oil composition to enhance thermal and oxidative stability of the oil, as well as to improve the performance of an industrial turbine housing the turbine oil composition. The isomerized base oil having consecutive numbers of carbon atoms and has less than 25 wt % naphthenic carbon by n-d-M. The turbine oil composition has a viscosity index of greater than about 150.

Abstract: A substantially non-aqueous liquid detergent composition which comprises: (a) perfume microcapsules; (b) no more than 20%, preferably no more than 15%, still more preferably no more than 10% by weight of water; (c) from 10% to 70%, preferably from 20% to 60% by weight of water-miscible organic solvent having a molecular weight greater than 70; and (d) from 30% to 90%, preferably from 40% to 80% by weight of one or more components comprising alkyl or alkenyl chains having more than 6 carbon atoms.

Abstract: The present invention is drawn to a aqueous composition containing: (a) at least one fatty quaternary amine compound; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous, and clear to substantially clear in appearance.

Abstract: The present invention is drawn to a aqueous composition containing: (a) at least one phospholipid compound; (b) at least one nonionic surfactant; (c) at least one phosphate ester chosen from alkoxylated alkyl phosphate esters and alkyl phosphate esters; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous, and clear to substantially clear in appearance.

Abstract: Bamboo vinegar is a natural product for sterilization and inhibition of bacteria growth and produces no pollution during the manufacturing process, and the discarded objects after the manufacturing process produce no pollution to the environment either. The bamboo vinegar added to shampoo for a pet's body and shampoo for a pet's hair have sterilization and antibacterial effects.

Abstract: A composition for cleaning dental instruments, comprising or consisting of: (a) one or more amino acids and/or salts thereof (aminocarboxylates) in a total amount of from 20 to 70 parts by weight, preferably 27.

Abstract: The current invention describes a formulation comprising of acetal or ketal as a solvent, a polyhydric alcohol, water and pH adjuster. These formulations should have a pH at least 7 or higher. Formulations in this invention can optionally contain water-soluble organic solvents as co-solvent, corrosion inhibitors and fluorides. The formulations in this invention can be used to remove post-etched organic and inorganic residue as well as polymeric residues from semiconductor substrates.

Abstract: The invention provides an aqueous shampoo composition comprising, in admixture: (i) a first anionic surfactant in which the ratio between the molecular weights of the polar (hydrophilic) and non-polar (hydrophobic) parts of the molecule is less than 1.5; (ii) a second anionic surfactant in which the ratio between the molecular weights of the polar (hydrophilic) and non-polar (hydrophobic) parts of the molecule is greater than 1.5, and (iii) a cationic polymer having a molecular weight of at least 100,000 Dalton and a cationic charge density of at least 0.5 meq/g; in which the weight ratio of (i):(ii) ranges from 3:1 to 1:3. Shampoo compositions according to the invention demonstrate reduced extensional viscosity (i.e. are less “stringy”). They also provide for the delivery of a significantly increased level of conditioning without any significant increase in product stringiness.

Abstract: A method of manufacturing a solvent from rubber tires includes a heated enclosure 66 through the heated a flow line with a temperature gradient of at least 150 F.°, and a rotary drum 74 in fluid communication with the flow line and condenser units 94, 98 to receive vapors output hydrocarbons. The solvent contains a high percent by weight of both limonene and naphthalene.

Abstract: Liquid washing and cleaning compositions are claimed, which comprise one or more anionic surfactants from the group of the alkylbenzenesulfonates, olefinsulfonates, alkylsulfonates, alkyl ether sulfonates together with sec. alkanesulfonate, and one or more components from the group of the soaps, ether carboxylates, betaines and a nonionic surfactant, and, as a dye fixative, homo- and copolymers of diallyldimethylammonium chloride or the reaction products of cyanamides with aldehydes and ammonium salts or cyanamides with aldehydes and monoamines or monoamines and/or polyamines with epichlorohydrin or polyamines with cyanamides and amidosulfuric acid.

Abstract: The present invention provides a treatment composition comprising a hydrophobic dye and a second dye, selected from hydrolysed reactive dyes, acid dyes and direct dyes; and a surfactant.

Abstract: A method of promoting activated, pleasant moods through the inhalation of energising, non-stressing fragrances (invigorating fragrances) comprising at least 75% by weight, preferably 85% by weight of perfume materials drawn from the following groups: A) At least 10% by weight in total of at least three materials drawn from Group ‘IMP’ comprising: allyl amyl glycolate; benzyl salicylate; bergamot oil; coriander oil; cyclamen aldehyde; 1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone; allyl (cyclohexyloxy)acetate; Damascenia 185 SAE; 2,4-dimethylheptan-1-ol; fir balsam; fir needle oil; 3-(4-ethylphenyl)-2,2-dimethylpropanal; ginger oil; guaiacwood; linalyl acetate; litsea cubeba oil; methyl 2,4-dihydroxy-3,6-dimethylbenzoate; nutmeg oil; olibanum oil; orange flower oil; Ozonal AB 7203C; patchouli oil; rose oxide; rosemary oil; sage clary oil; spearmint oil; Tamarine AB 8212E; tarragon oil; B) Optionally up to 90% of materials from the following groups: Group ‘HMR’ comprising: allyl ionone; benzyl acet

Abstract: Fragrance composition targeted at delivering well-being benefits through fragrant, low level positive mood stimulation. The composition comprises at least 75% by weight of perfume materials comprising at least 5% by weight of at least three materials drawn from Group ‘HMP’ comprising, for example, 1-(2,6,6,8-tetramethyltricyclo[5.3.1.0{1,5}]undec-8-en-9-yl)ethanone; allyl cyclohexylpropionate; allyl heptanoate; Apple Oliffac S pcmf; 7-methyl-2H-1,5-benzodioxepin-3(4H)-one; cassis base; and optionally up to 95% of materials selected from groups identified as Groups “HMR”, “HMI”, “RMP”, “IMP” and “Gen”, represented respectively by, for example, allyl ionone; dihydromyrcenol; anisic aldehyde; allyl amyl glycolate and cyclopentadecanolide; in specified relationships.

Abstract: The present invention relates to a peptide promoting cell adhesion and spreading, fragments, and derivatives thereof, more particularly, integrin-?3?1-dependent peptide in human laminin-5 ?3 chain LG3 domain, mediating integrin ?3?1 binding and cell adhesion and spreading, fragments and derivatives thereof. The inventive peptide, fragments and derivatives thereof can be used effectively for research on cell adhesion activity, wound care, tissue regeneration, inhibition of cancer metastesis etc. mediated by various extracellular matrix protein including laminin.

Abstract: There is provided the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of cancer. Such medicaments may be used in the treatment of tumours, including avascular tumours. Suitable agents to be used may preferably include the class III SLRPs opticin; epiphycan; or mimecan. The invention also provides a method for the prevention and/or treatment of cancer.

Abstract: The invention relates to the use of a peptide mixture comprising peptides with a molecular weight from 1000 to 5000 Daltons for the prevention and/or treatment of tumour diseases, of diseases which are associated with a development disorder of the immune system, of diseases of the immune system, of autoimmune reactions, of allergies and of inflammation in man, a protein component which contains such a peptide mixture and a formula food containing this peptide mixture. The peptides are preferably obtained from non-human proteins suitable for nutritional purposes, in particular by the enzymatic or hydrolytic cleavage of these proteins.

Abstract: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

Abstract: Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa (SEQ.ID.NO.: 1) in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any amino acid, Xaa at position 3 represents any amino acid and Xaa at position 4 represents Glu or Asp, each of the meanings of Xaa being independent, and peptides which consist of or comprise the sequence PYSSTA, particularly when in multimeric form, mimic the beneficial trophic and neuritogenic effects of FGF but lack the undesirable mitogenic effects. They are useful for the treatment of conditions for which FGF has been proposed, including treatment of neurodegenerative diseases, ischaemia, wound healing and stimulation of angiogenesis in cardiac muscle.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension of the retention time of the intracellular enzymes and signaling molecules that play important roles to proliferate, differentiate, maturate, and/or mineralize the hard tissue forming cells.

Abstract: Novel compounds, compositions comprising compounds, and methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, restenosis, sepsis, type 1 diabetes, liver damage, COPD, emphysema and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity.

Abstract: Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. Following administration, these formulations are rapidly absorbed into the blood stream. The formulation is preferably a polymeric gel, powder or film which adheres to the mucosal surface, thereby enhancing uptake of the incorporated drug. In the preferred embodiment, this formulation is administered sublingually, most preferably before a meal or after a meal.

Abstract: Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.

Abstract: Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

Abstract: The present invention includes compositions containing carboxymethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes thiol protecting group and where the hemoglobin is incapable of binding with the nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation, process of preparation and the method of supplementing blood in mammals.

Abstract: A two-stage method of preparing essentially pure amino acid chelates, wherein the first stage comprises contacting a metal ion from a metal oxide or hydroxide with an amino acid thereby producing a metal hydroxyl amino acetate. The second stage comprises contacting the metal hydroxyl amino acetate from the first stage, with at least one amino-containing compound provided in excess thereby producing a reaction solution containing an amino acid chelate reaction product comprising a metal ion bound to a plurality of amino acid ligands wherein the plurality of amino acid ligands is equal to the coordination number of the metal ion, and then separating the amino acid chelate from the reaction solution. The second stage may include a plurality of steps for sequentially reacting the reaction product with a plurality of amino-containing compounds. The amino acid chelates thus produced can be incorporated into compositions comprising beverages, foodstuffs, nutraceuticals and pharmaceutical adjuvants.

Abstract: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation, process of preparation and the method of use including supplementing blood volume in mammals and treating disorders in mammals where oxygen delivery agents are of benefit.

Abstract: The present invention provides compositions and methods for treating or preventing microbial infections.

Abstract: The present invention comprises a VPAC-2 receptor agonist of the formula (I): or a pharmaceutically acceptable salt thereof. Underlined residues indicate a side-chain to side-chain covalent linkage of the first and last amino acids within the segment. The present invention also encompasses pharmaceutical compositions containing such agonists, and the use of such agonists for the treatment of pulmonary diseases including COPD.

Abstract: Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.

Abstract: The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically viral replication and transmission.

Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.

Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.